The aim of the study was to determine treatment outcome and identify a particularly high risk group in a consecutive series of 66 patients with poor prognosis high grade lymphoma (NHL) treated with conventional induction chemotherapy followed by high-dose chemotherapy (HDCT) and peripheral blood stem cells (PBSC) rescue. Fifty-one patients with intermediate grade NHL (Kiel) and two or three adverse prognostic features as defined by the age-adjusted International Prognostic Index (IPI) received induction treatment with 7 weeks of doxorubicin, cyclophosphamide, vincristine, bleomycin, etoposide, prednisolone and methotrexate (VAPEC-B) followed by three cycles of ifosfamide/cytarabine. Fifteen patients with high grade Burkitt's and lymphoblastic NHL received 11 weeks of VAPEC-B followed by three cycles of high-dose methotrexate. HDCT for all 66 patients consisted of busulphan/cyclophosphamide followed by autologous PBSC rescue. Thirty-one patients (47%) received HDCT in first complete remission (CR/CRu) and 34 patients (52%) in first partial remission (PR) after conventional chemotherapy. Following HDCT, 42 patients (64%) were in CR/CRu, 19 patients (29%) in PR and one patient had progressive disease. There were four toxic deaths. After a median follow-up period of 27 months (range 7-73) in 46 surviving patients, the actuarial 3-year estimates of overall survival, event-free survival (EFS) and freedom from progression (FFP) were 67%, 65% and 70%, respectively. In univariate analysis, prognostic factors associated with reduced EFS were mediastinal bulk (P = 0.02), у3 extra-nodal sites (P = 0.02), remission status prior to HDCT (P = 0.05), low albumin (P = 0.08) and raised ESR (P = 0.09). No significant difference was observed between patients with intermediate or high grade NHL or between patients with two or three adverse IPI features. Multivariate analysis identified mediastinal bulk (P = 0.01), у3 extra-nodal sites (P = 0.01) and low albumin (P = 0.03) as joint predictors of poor EFS. Remission status prior to HDCT was not found to be significantly associated with reduced EFS, FFP or survival, suggesting early introduction of HDCT may benefit patients with a PR. Based on these three adverse features, three groups (0, 1 or у2 features) could be identified with differing EFS, survival and freedom from progression (FFP) rates at 3 years; 85%, 63% and 20%, respectively for EFS, 84%, 64% and 25% for survival and 85%, 66% and 33%, respectively for FFP. This prognostic model may identify patients with a particularly poor prognosis despite HDCT, who may benefit from other therapeutic approaches.
The International Prognostic Index (IPI) was developed to predict the outcome of patients with high grade (Kiel classification) non-Hodgkin's lymphoma (NHL) treated with conventional chemotherapy. For patients with two or three adverse features the outlook following chemotherapy is poor with a 5-year survival of 46% and 32%, respectively.
1 Randomised phase III trials have shown no improvement in outcome with the use of second-and third-generation regimens for primary treatment of high aggressive lymphomas when compared with CHOP chemotherapy. 2, 3 In an effort to improve the results for patients with high risk aggressive lymphoma, haemopoietic growth factors and/or autologous peripheral blood stem cells have been used to significantly intensify therapies. Preliminary results demonstrated minimal or no benefit to intensification of standard regimens associated with using growth factor alone. 4, 5 In contrast, most uncontrolled phase II studies using HDCT suggest that this approach may be associated with improved survival with an estimated survival rate ranging from 63% to 85% at 3 years. [6] [7] [8] [9] [10] [11] In an initial study performed at this institute, we recently demonstrated a 30-40% advantage in event-free and overall survival for a single high-dose treatment when compared with a retrospective series of matched patients treated with standard chemotherapy. 11 In the present study, the outcome for 66 consecutive patients with poor prognosis high grade lymphoma treated with HDCT and peripheral blood stem cell (PBSC) transplantation in first remission (complete or partial) following standard-dose induction therapy is presented. For the induction treatment, we used a weekly outpatient regimen of alternating myelosuppressive and non-myelosuppressive drugs (doxorubicin, cyclophosphamide, vincristine, bleomycin, etoposide, prednisolone and methotrexate (VAPEC-B)) which we previously reported to produce a response rate of 91% and 4-year survival rate of 60%, comparable to those obtained with other regimens. 4, 12 We have previously shown that the combination of doxurubicin and etoposide in this regimen with granulocyte colony-stimulating factor is effective in mobilizing sufficient haemopoietic stem cells for PBSC tranplantation using a single apheresis. 13 Due to the high risk of relapse and poor outcome in patients with Burkitt's type and lymphoblastic lymphoma when treated with conventional therapy, [14] [15] [16] [17] [18] these patients were entered into the HDCT programme. We examined the prognostic factors associated with reduced freedom from progression, event-free survival and overall survival following HDCT. A better understanding of the prognostic features with this dose-intensive approach may identify a subset of patients who may benefit from additional therapy or an alternative approach.
Patients and methods
Sixty-six consecutive patients aged less than 60 years with poor prognosis high grade NHL received HDCT followed by PBSC rescue after conventional induction chemotherapy. Staging was based on Ann Arbor criteria (including the Cotswolds modification) 19 and resulted from a full history and physical examination, plain radiography of the chest, computed tomographic (CT) scan of the thorax, abdomen, and pelvis, complete blood count, serum biochemical profile and examination of a bone marrow aspirate and trephine biopsy. In addition, isotope bone scans, ultrasound scans and biopsies of suspicious lesions were performed where necessary. Peripheral and abdominal nodal masses у10 cm in any diameter or, in the mediastinum, masses with a transverse diameter у0.33 of the internal thoracic diameter at the level of the D5/6 intervertebral disc were considered bulky. Tumour response rates were documented according to the International Union Against Cancer (UICC) criteria with an additional category termed uncertain complete remission (CRu) which denotes complete resolution of all disease but residual radiographic abnormalities of uncertain significance, based on the Cotswold consensus report. 19 
Treatment, PBPC collections, HDCT and PBPC reinfusion
Fifty-one patients with high grade (Kiel classification) NHL received 7 weekly cycles of VAPEC-B chemotherapy according to the dose and schedule described previously. 11, 20 On the day following the last dose of oral etoposide at week 7, they commenced G-CSF (filgrastim 300 g/d or 5 g/kg if body weight Ͼ70 kg, Amgen, Cambridge, UK) given by daily subcutaneous injection. Leukapheresis was performed on the day of anticipated maximum PBSC release and the cells were cryopreserved. Following this, three cycles of consolidation chemotherapy with ifosfamide (3 g/m 2 ) and cytarabine (800 mg/m 2 ) were given as described previously. 11, 20 Patients with Burkitt's and lymphoblastic lymphoma received 11 weekly cycles of VAPEC-B chemotherapy (with alternate weekly intrathecal methotrexate (12.5 mg)) followed by three cycles of highdose methotrexate (3 g/m 2 ) with folinic acid rescue given at 2 weekly intervals. The HDCT consisted of oral busulphan 4 mg/kg/day given orally in divided doses for 4 days (total 16 mg/kg) as an outpatient, followed by cyclophosphamide 50 mg/kg/day (total 200 mg/kg) with intravenous mesna for 4 days. The PBSCs were reinfused intravenously 48 h after the last dose of chemotherapy. Following HDCT, patients with mediastinal bulk or residual disease on restaging CT scan were offered radiotherapy treatment. The median time from start of induction chemotherapy to HDCT was 6 months (range 3-8).
Supportive measures
Prophylactic medication including oral phenytoin, cotrimoxazole, fluconazole, acyclovir and low-dose heparin was given to all patients. Post-HDCT, a full blood count and differential were measured daily until the granulocyte count was Ͼ1.0 × 10 9 /l for 2 consecutive days. As soon as fever equal to or greater than 38.0°C occurred, blood cultures were taken and empiric i.v. antibiotic treatment was initiated. Packed red blood cells and donor platelet tranfusions were used to maintain a haemoglobin у9 g/l and platelets у20 × 10 9 /l and all blood products were irradiated to 25 Gy. Patients who were cytomegalovirus (CMV) negative received blood products from CMV-negative donors. Patients were discharged from hospital when they were clinically well, had been apyrexial and off i.v. antibiotics for 24 h, and had a granulocyte count Ͼ1.0 × 10 9 /l.
Parameters evaluated
The variables studied were age, gender, B symptoms, histology, mediastinal bulk, disease bulk at other sites, number of age-adjusted IPI features at presentation, number of extra-nodal sites, performance status at presentation and immediately prior to HDCT, remission status (CR, CRu, PR) following induction therapy, haemoglobin, white cell count, lymphocyte count, platelet count, erythrocyte sedimentation rate, serum sodium, serum albumin, serum globulin, serum alkaline phosphatase, serum aspartate transaminase, serum bilirubin, serum gamma transpeptidase at presentation, serum lactate dehydrogenase and Karnofsky performance at presentation and prior to HDCT.
Statistics
Disease end-points analysed were freedom from progression (FFP; defined as time to first disease progression), event-free survival (EFS; defined as time to the first of either disease progression or death from an unrelated cause) and overall survival (OS). FFP, EFS and OS functions were estimated using the Kaplan-Meier method. The relationship of the clinical features outlined above to the various outcomes was analysed individually and then by multivariate analysis using Cox regression. Covariate transformations were assessed with smoothed-scaled Martingale residual plots 21 and proportional hazards were checked using smoothed partial residual plots. 22 There were some missing data on some of the laboratory variables (most notably ESR with 16 missing observations). Cases with missing data on particular variables were excluded from analysis involving that variable.
Results

Patients characteristics
Sixty-six consecutive patients (42 men and 24 women) received high-dose chemotheray following induction chemotherapy. Fifty-one patients had high grade NHL (Kiel classification) with two or three adverse features (stage III or IV disease, raised serum lactate dehydrogenase level, and Karnofsky performance status р70) as defined by the international NHL prognostic index.
1 Twelve patients had lymphoblastic NHL and three patients Burkitt-type NHL. The median age of this patient population was 39 years (range, 16-60). Apart from one patient (see below), all patients were in CR/CRu or PR following induction chemotherapy. Thirty-seven patients had three risk factors, 24 patients two risk factors and five patients р2 risk factors according to age-adjusted international index. Their pretreatment characteristics are listed in Table 1 .
Disease response and transplant-related mortality
Response to induction chemotherapy was evaluated just before HDCT and 60-100 days after HDCT. All patients (except one) achieved a remission following induction chemotherapy: 31 patients (47%) a CR or CRu and 34 patients (52%) a PR. One patient was found to have a palpably enlarged lymph node immediately prior to the HDCT but a decision was made to proceed with the planned treatment. No response was seen in this patient despite the treatment. Following HDCT, 42 patients (64%) achieved a CR or CRu and 19 patients (29%) remained in PR. Four treatment-related deaths were seen; these occurred soon after the HDCT programme was first introduced. Three patients died of autopsy documented hepatic veno-occlusive disease after presenting with either fulminant liver failure, variceal bleeding from portal hypertension and hepatic encephalopathy on days 37, 66 and 73 post tranplant, respectively. One patient died on day 101 from pulmonary haemorrhage following a lung biopsy performed for investigation of pulmonary opacities. At post mortem interstitial pneumonitis was found and this was thought to represent busulphan toxicity. No deaths have been seen since the introduction of low-dose heparin prophylaxis post HDCT (in an attempt to reduce the incidence of hepatic veno-occlusive disease) and after changing the busulphan schedule to divided daily doses instead of a single dose schedule.
Engraftment
The median number of CD34 cells collected was 8.3 × 10 6 cells/kg. The median number of days following stem cell re-infusion to reach an absolute granulocyte count of 1.0 × 10 9 /l was 10 days (range, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] and the median time to a self-sustaining platelet count greater than 20 × 10 9 /l was 10 days (range, 6-86). The majority of these patients had infectious episodes during the neutropenic phase requiring parenteral antimicrobials treatment.
Patient outcome
After a median follow-up for survivors of 27 months (range, 7-73), 43 patients (65%) are alive and disease-free. The actuarial 3-year estimates of OS, EFS and FFP are 67%, 65% and 70%, respectively (see Figure 1) . When the group was separated on the basis of age-adjusted IPI risk groups, the 3-year OS, EFS and FFP were 63%, 59% and 66%, respectively, in the high risk group (three risk factors) and 75%, 71% and 74% in the intermediate-high risk group (two risk factors) (see Figure 2 for EFS). In addition, for the subset of 15 patients with Burkitt's/lymphoblastic lymphoma, the estimated 3-year OS, EFS and FFP were 72%, 66% and 66%, respectively, not significantly different from the subset of 51 patients with high grade Kiel with an estimated 3-year OS, EFS and FFP of 66%, 65% and 71%, respectively. For the subsets of patients with CR, CRu and PR status, the estimated 3-year data were 81%, 64%, 64% for OS, 82%, 57%, 62% for EFS and 82%, 62%, 68% for FFP. Despite an observed difference in outcome between CR and CRu status, there was no statistically significant difference in outcome between CR, CRu and PR patients (see Figure 3 for EFS, P = 0.14).
Relapse
Nineteen patients have relapsed following HDCT with a median time to relapse of 4.1 months (range, 1.7-8.9). No relapses were seen after the 9 months point. At relapse, 11 were treated with salvage chemotherapy, three with radiotherapy and three with combined chemotherapy and radiotherapy. Despite these treatments, the prognosis of these patients was poor with only three patients currently alive (two following chemotherapy and one following XRT). The estimated median survival following relapse was 4 months (see Figure 4) .
Regression analysis
Univariate analysis of the characteristics listed above was undertaken to select covariates for multivariate analysis. In univariate analysis, prognostic factors associated with reduced EFS were mediastinal bulk (P = 0.02), у3 extranodal sites (P = 0.02), remission status prior to HDCT (P = 0.05), low albumin (P = 0.08) and raised ESR (P = 0.09). No significant difference was observed for EFS between patients with Burkitt's/lymphoblastic lymphoma or high grade Kiel histology or between patients with two or three adverse IPI features (Figure 2 ). Similar prognostic results were obtained for FFP and overall survival. Multivariate analysis identified mediastinal bulk (P = 0.01), у3 extra-nodal sites (P = 0.01) and low albumin (P = 0.03) as joint predictors of poor EFS (see Table 2 ). PR status prior to HDCT was not found to be significantly associated with reduced EFS, FFP or survival suggesting early introduction of HDCT may benefit patients with a PR. A cutpoint of 34 g/l was chosen for albumin to give a regression coefficient similar to that obtained for the other two discrete variables in the model and based on these three adverse features, three groups (none, one or у2 features) could be identified with differing EFS, survival and FFP rates at 3 years; 85%, 63% and 20%, respectively, for EFS, 84%, 64% and 25% for survival and 85%, 66% and 33%, respectively for FFP. Figure 5a -c illustrates the KaplanMeier plots of FFP, EFS and overall survival according to the number of risk factors present.
Discussion
For patients with NHL and adverse prognostic features at presentation, the results of conventional doxorubicin-based chemotherapy are poor with high risk patients achieving a CR rate of only 40% and 26% long-term survival against an 87% CR rate and 73% survival rate for low risk patients. 1 These results were recently validated in a separate cohort of 426 patients with two or more IPI risk factors where a CR rate of less than 30% and a 5-year survival rate of less than 15% were reported. 23 In an effort to improve these results, high-dose chemotherapy (HDCT) is increasingly being used to treat patients following remission induction with the aim of eliminating minimal disease that might otherwise cause relapse. Most phase II studies have shown promising results [6] [7] [8] [9] [10] [11] although some reports found no benefits 24, 25 with the use of HDCT. There are a number of ongoing randomised clinical trials addressing the role of first remission transplantation. Two randomised phase III studies with different trial designs were published recently in which HDCT and autologous bone marrow transplantation have been compared with conventional chemotherapy in patients with two or more IPI risk factors. Gianni et al 26 showed a considerable advantage for high-dose sequential chemotherapy when compared with conventional chemotherapy, suggesting that early intensification was more effective than intensive chemotherapy given at the time of disease progression. The trial randomised 98 high-risk patients to receive either MACOP-B (n = 48) or high-dose sequential (HDS) chemotherapy (n = 50). The 7-year EFS rates were 76% for HDS and 49% for MACOP-B and OS rates were 81% for HDS and 55% for MACOP-B. Unfortunately the study was restricted to patients with just diffuse large cell NHL without bone marrow infiltration. Haioun et al 27 using a different trial design, found single consolidative HDCT was superior to sequential standard-dose chemotherapy regimens for poor risk patients in CR following induction chemotherapy with six cycles of ACVB (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisolone). A subset analysis of their 236 patients considered high risk by age-adjusted IPI criteria (у2 risk factors) showed superior 5-year disease-free survival (59% vs 39%) and OS (65% vs 52%) for the HDCT arm compared with conventional chemotherapy. Unfortunately this sub-analysis does not allow firm conclusions to be drawn from a statistical point of view. For patients with a partial response, the role of consolidative HDCT has not been established. Two small randomised trials investigated whether patients in partial response following three or four cycles of standard chemotherapy would benefit from consolidative HDCT. An Italian group randomised 49 patients (of 77 eligible for randomization) in partial remission following 8 weeks of MACOP-B or four cycles of F-MACHOP to single HDCT or conventional dose-salvage DHAP. They demonstrated an improved FFP (73% vs 52%) and OS (73% vs 59%) for HDCT but this did not reach statistical significance because of the small number of patients. 28 An earlier Dutch study with 69 patients (of 106 eligible patients) was not able to demonstrate an improved EFS or overall survival 24 but this study was criticised for including a majority of low risk patients and for assessing early responses to imprecise standard criteria.
In the current series of high risk patients, the overall survival, event-free survival (EFS) and freedom from progression (FFP) at 3 years were 67%, 65% and 70%, respectively, results which compare favourably with most published phase II/III studies, [6] [7] [8] [9] [10] [11] 25, 26, 27 particularly when we included patients with partial remission following conventional chemotherapy. We also included patients with Burkitt's or lymphoblastic lymphoma in our series as prognosis in these groups of patients remains poor with a high relapse rate and few long-term survivors when treated with conventional chemotherapy.
14-18 Subgroup analysis of our 15 patients with Burkitt's/lymphoblastic lymphoma showed a similar survival pattern to that of the remaining high risk non-Burkitt/lymphoblastic patients with two or more IPI risk features; the estimated 3-year EFS rates were 66% vs 65%, respectively. This result compared favourably with the EBMT data which reported a 72% 3-year overall survival rate for 70 patients with Burkitt's lymphoma 29 and 63% overall survival for 105 adult patients with lymphoblastic lymphoma 30 transplanted in first complete remission. Thus, in patients with Burkitt's/lymphoblastic lymphoma, a subset for whom conventional therapy gives relatively poor results, [14] [15] [16] [17] [18] the 66% long-term EFS rate produced by our brief induction/single consolidative approach may offer considerable advantages.
It is of note that in our series, patients in complete or partial remission following induction chemotherapy received HDCT with autologous haematopoietic rescue. At the time of HDCT, 34 (52%) of our patients were in PR and following HDCT, 19 (29%) of these remained in PR; the actuarial 3 year survival for this group of patients (n = 34) was 63%. Furthermore, on multivariate analysis, PR status was found not to be associated with poorer outcome suggesting that early introduction of HDCT before disease progression may benefit patients with a PR following conventional chemotherapy. In contrast, the outcome of patients who achieve a PR following conventional chemotherapy alone remains poor, with reported median survival duration ranging from 5 to 14 months and the probability of survival at 24 months ranging between 0 and 29%. This is despite the use of intensive radiation and/or chemotherapy salvage treatments at relapse. 31 We also carried out further analysis to evaluate whether factors already known to predict a poor prognosis in patients with newly diagnosed disease similarly predict poor outcome after HDCT. Multivariate analysis identified mediastinal bulk, у3 extra-nodal sites and low albumin as joint predictors of poor OS. Based on these adverse features, three groups (none, one or у2 features) could be identified with differing overall survival; 84%, 64% and 25%, respectively. For very poor risk patients where only 25% survive 3 years after HDCT, alternative or additional therapies need to be considered.
The role of HDCT in poor prognostic high grade NHL remains to be established despite two favourable reports alluded to earlier. There are several ongoing studies addressing this issue (MISTRAL and American Cooperative Group studies). Moreover, several variations of HDCT have been described. The sequential high-dose approach reported by Gianni et al 26 appears the most promising with an impressive 96% complete remission rate in contrast to our study of 64%. Similarly, in a series of 52 patients with poor prognosis lymphoma, Nademanee et al 10 recently reported 84% OS and 82% FFP rates. In both series, very high complete remission rates (70% and 76%, respectively) were reported following standard induction chemotherapy which is contrary to most published data. On the other hand, the Eastern Cooperative Oncology Group (ECOG) 32 in a pilot study reported only 73% OS and 61% FFP with high-dose sequential chemotherapy in comparison to the original report of 81% OS and 84% FFP. 26 In addition, we do not know whether repetitive HDCT is superior to single consolidative HDCT. The relatively good results of our approach must be balanced against the likely risk of increased procedure-related mortality/morbidity and the potential late complications with additional HDCT (especially, second malignancy, cardiac and pulmonary dysfunction). To date, no second malignancies have been seen in our series and this might be related to the fact that our patients received high-dose chemotherapy early, thus avoiding exposure of haematopoietic stem cells to repeated cycles of salvage therapy. It is possible that all variations of HDCT may yield similar results due to intrinsic drugresistant tumour cells that permit only about 50-70% of poor risk patients to be cured by these measures, a scenario which is commonly seen in leukaemic populations.
In conclusion, the results presented here suggest that induction chemotherapy followed by HDCT and peripheral blood stem cell rescue may improve the prognosis of patients with high grade NHL and adverse features according to the age-adjusted International Prognostic Index. Importantly, this appears to be the case irrespective of whether a CR or PR was achieved with induction chemotherapy. In addition, we have identified features pre-HDCT which may permit selection of certain subgroups of patients likely to achieve less than optimal benefit from costly and potentially morbid dose-intensive treatment for whom alternative therapeutic approaches are required.
